Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lyon
Clinical trial register · France

Clinical Trials in Lyon, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9698 matching records held by the registry are in this view. Synced 23 Oct 2026, 03:20 UTC
9698
Studies in scope
all four open statuses
6023
Recruiting now
open to new participants
1034
Lead sponsors
across recruiting studies
Top sites
Paris 64 Bordeaux 62 Montpellier 61 Lyon 60 Marseille 58
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hospices Civils de Lyon187 AstraZeneca60 Centre Leon Berard51 GCS Ramsay Santé pour l'Enseignement et la Recherche36 Hoffmann-La Roche33 Clear sponsor filter
Site location
Paris64 Bordeaux62 Montpellier61 Lyon60 Marseille58
All 106 locations
Target enrolment
to

Trials with a site in Lyon

60 of 9698 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
AstraZeneca
Phase 3
7,000
Corbeil-Essonnes, Grenoble, La Rochelle, Laval, Le Puy-en-Velay, Lyon, Metz-Tessy, Montpellier
2026-08-21
Recruiting
AstraZeneca
Phase 3
59
Aix-en-Provence, Brest, Colmar, Gleizé, Grenoble, Lyon, Marseille, Montpellier
2026-05-05
Recruiting
AstraZeneca
Phase 3
245
Clermont-Ferrand, Lyon, Marseille, Paris, Pessac, Saint-Denis, Saint-Pierre, Toulon
2026-04-13
Recruiting
AstraZeneca
Phase 2
43
Bordeaux, Créteil, Lyon, Nantes, Nîmes
2026-03-28
Recruiting
AstraZeneca
Phase 3
2,130
Bordeaux, Caen, Lyon, Marseille, Rennes, Villejuif
2026-02-03
Recruiting
AstraZeneca
Phase 2
230
Lyon, Montpellier, Nantes, Nîmes, Paris, Tours
2025-12-10
Recruiting
AstraZeneca
Phase 3
400
Boulogne-Billancourt, Lyon, Marseille, Saint-Herblain, Toulouse
2025-10-31
Recruiting
AstraZeneca
Phase 1/2
283
Lyon, Montpellier, Saint-Herblain, Suresnes, Villejuif
2025-10-01
Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab
AstraZeneca
Phase 2
150
Angers, Bordeaux, Chambray-lès-Tours, Dijon, Lille, Lyon, Marseille, Montpellier
2025-05-15
Recruiting
AstraZeneca
Phase 3
1,220
Clichy, Lille, Lyon, Montpellier, Nantes, Nice, Pessac, Rennes
2025-05-06
Recruiting
AstraZeneca
Phase 3
600
Besançon, Bordeaux, Caen, Clermont-Ferrand, Lyon, Montpellier, Nice, Paris
2025-03-27
Recruiting
AstraZeneca
Phase 2
540
Brest, Créteil, Lyon, Marseille, Pessac, Strasbourg, Suresnes
2025-03-26
Recruiting
AstraZeneca
Phase 3
990
Brest, Lyon, Marseille, Montpellier, Paris, Pessac, Saint-Herblain
2025-03-25
Recruiting
AstraZeneca
Phase 3
840
Bordeaux, Caen, Clermont-Ferrand, Dijon, Lyon, Marseille, Poitiers, Rennes
2025-03-01
Recruiting
AstraZeneca
Observational
126
Clermont-Ferrand, Gleizé, Grenoble, Lyon, Metz-Tessy, Saint-Etienne, Saint-Priest-en-Jarez, Thonon-les-Bains
2024-12-30
Recruiting
AstraZeneca
Phase 3
1,160
Avignon, La Rochelle, Lyon, Nîmes, Rennes, Strasbourg, Suresnes, Toulon
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Avignon, La Rochelle, Lyon, Nîmes, Rennes, Strasbourg, Suresnes, Toulon
2024-11-18
Active, closed
AstraZeneca
Phase 3
310
Créteil, La Tronche, Lyon, Marseille, Montpellier, Strasbourg
2024-09-30
Recruiting
AstraZeneca
Phase 3
620
Brest, Clichy, Dijon, Lille, Lyon, Marseille, Montpellier, Pessac
2024-08-12
Recruiting
AstraZeneca
Phase 3
788
Angers, Besançon, Lille, Lyon, Marseille, Paris, Rouen, Saint-Herblain
2024-08-01
Active, closed
AstraZeneca
Phase 3
339
Bois-Guillaume, Dijon, Lyon, Montivilliers, Nantes, Paris, Poitiers, Toulouse
2024-06-29
Recruiting
AstraZeneca
Phase 3
240
Angers, Brest, Le Mans, Lille, Lyon, Paris, Reims, Rouen
2024-06-20
Active, closed
AstraZeneca
Phase 3
594
Besançon, Brest, Lille, Lyon, Nantes
2024-03-04
Recruiting
AstraZeneca
Phase 3
1,145
Avignon, Bordeaux, Le Mans, Lyon, Nice, Saint-Herblain, Toulouse, Villejuif
2023-12-14
Recruiting
AstraZeneca
Phase 3
625
Lille, Lyon, Montpellier, Paris, Saint-Herblain, Toulouse, Vandœuvre-lès-Nancy, Villejuif
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,898
Angers, Bayonne, Bordeaux, Caen, Clermont-Ferrand, Créteil, Lyon, Montpellier
2023-11-21
Active, closed
AstraZeneca
Phase 3
863
Brest, Créteil, Le Mans, Lille, Lyon, Marseille, Montpellier, Paris
2023-11-09
Active, closed
AstraZeneca
Phase 3
5,511
Angers, Bordeaux, Caen, Clermont-Ferrand, Dijon, Epagny Metz-Tessy, Lille, Lyon
2023-10-05
Active, closed
AstraZeneca
Phase 3
94
Créteil, Lyon, Rouen
2023-04-05
Active, closed
AstraZeneca
Phase 3
1,174
Angers, Bordeaux, Dijon, Lyon, Montpellier, Nîmes, Paris, Poitiers
2022-11-28
Active, closed
AstraZeneca
Phase 3
594
Angers, Clamart, Clermont-Ferrand, Créteil, Lyon, Montpellier, Nantes, Paris
2022-09-15
Recruiting
AstraZeneca
Phase 2
454
Bordeaux, Lyon, Marseille, Suresnes
2022-09-06
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Amiens, Angers, Bordeaux, Lille, Lyon, Marseille, Paris, Rennes
2022-05-23
Active, closed
AstraZeneca
Phase 3
644
Bordeaux, Dijon, Limoges, Lyon, Marseille, Montpellier, Paris, Rouen
2022-05-16
By invitation
AstraZeneca
Phase 3
214
Besançon, Bordeaux, Brest, Dijon, Lyon, Marseille, Montpellier, Rennes
2022-04-19
Active, closed
AstraZeneca
Phase 3
145
Créteil, Lyon, Toulouse
2021-11-19
Active, closed
AstraZeneca
Phase 3
454
Bordeaux, Dijon, Le Mans, Lyon, Marseille, Nantes, Toulouse, Villejuif
2021-10-28
Active, closed
AstraZeneca
Phase 3
732
Bezannes, Bordeaux, Lille, Lyon, Montpellier, Plérin, Toulouse, Villejuif
2021-10-18
Active, closed
AstraZeneca
Phase 3
712
Amiens, Bayonne, Clermont-Ferrand, Lille, Lyon, Marseille, Montpellier, Nice
2021-08-05
Active, closed
AstraZeneca
Phase 3
315
Avignon, Brest, Clermont-Ferrand, Dijon, Limoges, Lorient, Lyon, Marseille
2021-06-30
Active, closed
AstraZeneca
Phase 3
893
Bobigny, Limoges, Lyon, Plérin, Rouen, Saint-Herblain, Villejuif
2021-05-10
Active, closed
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
102
Bordeaux, Lyon, Villejuif
2020-12-30
Active, closed
AstraZeneca
Phase 3
957
Avignon, Besançon, Brest, Dijon, Lyon, Montpellier, Nantes, Nice
2020-11-17
Active, closed
AstraZeneca
Phase 3
640
Besançon, Lille, Lyon, Montpellier, Reims, Rouen, Strasbourg, Villejuif
2020-10-19
Active, closed
AstraZeneca
Phase 3
370
Avignon, Bordeaux, Clermont-Ferrand, Dijon, Lyon, Marseille, Montpellier, Strasbourg
2020-10-02
Active, closed
AstraZeneca
Phase 3
185
Lille, Lyon, Plérin, Villejuif
2020-08-04
Active, closed
AstraZeneca
Phase 3
587
Bordeaux, Lyon, Montpellier, Villejuif
2019-07-02
Active, closed
AstraZeneca
Phase 3
923
Brest, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain, Villejuif
2019-06-25
Active, closed
AstraZeneca
Phase 3
724
Bron, Dijon, Lyon, Nantes, Pierre-Bénite, Toulouse, Villejuif
2019-03-06
Active, closed
AstraZeneca
Phase 3
1,407
Besançon, Bordeaux, Limoges, Lyon, Marseille, Nantes, Paris, Saint-Herblain
2019-01-04
Active, closed
AstraZeneca
Phase 3
825
Avignon, Lyon, Nice, Toulon, Vantoux
2018-12-06
Active, closed
AstraZeneca
Phase 3
1,018
Amiens, Angers, Bordeaux, Lyon, Marseille, Montpellier, Strasbourg, Suresnes
2018-05-14
Active, closed
AstraZeneca
Phase 2
273
Angers, Besançon, Bordeaux, Caen, Lille, Lyon, Marseille, Montpellier
2018-03-07
Active, closed
AstraZeneca
Phase 1
117
Bordeaux, Caen, Lyon, Marseille, Saint-Herblain, Toulouse
2016-12-28
Active, closed
AstraZeneca
Phase 3
1,126
Bordeaux, Caen, Lyon, Marseille, Paris, Poitiers, Suresnes, Toulouse
2015-11-02
Active, closed
AstraZeneca
Phase 3
682
Bron, Lille, Limoges, Lyon, Paris
2015-10-21
Active, closed
AstraZeneca
Phase 3
1,118
Bordeaux, Brest, Créteil, Lille, Lyon, Marseille
2015-07-21
Active, closed
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
DrugsSaruparib·Olaparib·Durvalumab·Carboplatin
AstraZeneca
Phase 1
358
Bordeaux, Lyon, Saint-Herblain, Villejuif
2014-10-31
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Bordeaux, Caen, Lyon, Nantes, Paris, Pierre-Bénite, Saint-Cloud, Toulouse
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Bordeaux, Caen, Lyon, Nantes, Paris, Vandœuvre-lès-Nancy, Villejuif
2013-08-26
Rows per page Showing 1–60 of 60
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 October 2026. https://priyalifescience.com/clinical-trials-france/city/lyon

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,698 studies in total at the last sync on 23 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 60 of those studies with a site in Lyon that also match the filters currently applied.

How many clinical trials are recruiting in Lyon?

23 of the 60 studies on this page are recruiting new participants as of the 23 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 36 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lyon), 60 studies
PhaseStudiesRecruitingShare
Phase 3481680%
Phase 27511.7%
Observational213.3%
Phase 1203.3%
Phase 1/2111.7%

Most active sponsors

Lead sponsors with the most studies (Lyon)
Lead sponsorStudiesRecruiting
AstraZeneca6023
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.